Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a serious condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.
Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.
Please be aware that we are currently receiving numerous reports of fraudulent activity where individuals are posing as Tricida, Inc. recruiters, seeking to engage with job seekers through fraudulent online advertisements, job search sites, and direct email solicitations. These unauthorized individuals are using Tricida’s name and logo in an attempt to solicit up-front fees and obtain personally identifiable information from interested job seekers. Please know that Tricida does not conduct interviews via chat rooms such as Google Hangouts, use apps similar to Signal, charge candidates an advance fee of any kind (e.g., fees for purchasing equipment), nor does it offer positions of employment without undergoing a thorough recruiting process. Please also note that any correspondence with regard to employment would come from an authorized Tricida.com email address such as firstname.lastname@example.org. If you receive unsolicited offers of employment from people claiming to work for Tricida, we recommend that you do not respond to their inquiries, do not open any attachments, do not click on any hyperlinks, and alert Tricida Human Resources at email@example.com.
DOL Required Transparency Rules: Cigna Readable File Link